Pancreatic Cancer Clinical Trials in Tennessee

Showing 81-85 of 85 trials

A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

NCT00179751

Phase I will determine the MDT and evaluate the safety profile of oral lenalidomide days 1-21 and weekly gemcitabine days 1, 8, \& 15 in 28 day cycles Phase II will explore the anti-tumor activity and safety of the combination in subjects with advanced pancreatic carcinoma. Subjects will receive oral lenalidomide days 1-21 and weekly gemcitabine days 1, 8, \& 15 in 28 day cycles until documented disease progression occurs.

Pancreatic Cancer

Celgene Corporation50 participantsStarted Apr 2005

Metairie, Louisiana, United States • St Louis, Missouri, United States • Cleveland, Ohio, United States +3 more locations

TERMINATEDPHASE2174 miles

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

NCT00326911

Eligible patients with metastatic pancreatic cancer will be treated with dual agent monoclonal antibody consisting of cetuximab and bevacizumab alone or in combination with gemcitabine

Metastatic Pancreatic Cancer

Eli Lilly and Company61 participantsStarted May 2006

Jonesboro, Arkansas, United States • San Francisco, California, United States • Stamford, Connecticut, United States +13 more locations

A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

Pancreatic Cancer Trials in Other Cities

Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

Other Conditions in Tennessee